Table 4.
Adjusted association between tacrolimus intrapatient variability and C1q-binding de novo donor-specific antibody formation in the outcome cohort
| Variable | Hazard Ratio (95% Confidence Interval) | ||
|---|---|---|---|
| Model 1a | Model 2b | Model 3c | |
| Tacrolimus IPV (continuous variable) | 1.04 (1.03 to 1.05) | ||
| Tacrolimus IPV >30% | 5.35 (2.45 to 11.68) | ||
| Tacrolimus IPV, quartiles d | |||
| First | — | ||
| Second | 3.35 (1.27 to 8.88) | ||
| Third | 3.54 (0.93 to 13.39) | ||
| Fourth | 11.81 (4.76 to 29.27) | ||
Tacrolimus IPV was used as a time-dependent variable. IPV, intrapatient variability; —, not analyzed.
Tacrolimus IPV as a continuous variable adjusted for age at transplantation and peak panel reactive antibody.
Tacrolimus IPV categorized as under or over 30% adjusted for age at transplantation and peak panel reactive antibody.
Tacrolimus IPV categorized by quartiles adjusted for age at transplantation and peak panel reactive antibody.
Tacrolimus IPV cutoffs by quartiles calculated from entire cohort: first quartile (25th percentile): 21%; second quartile (50th percentile): 30%; third quartile (75th percentile): 41%; fourth quartile (100th percentile): 173%.